Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
Runzhe Chen, Baoan Chen Department of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People’s Republic of China Abstract: Brentuximab vedotin is a promising antibody–drug conjugate (ADC) tar...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2015-03-01
|
| Seri Bilgileri: | Drug Design, Development and Therapy |
| Online Erişim: | http://www.dovepress.com/brentuximab-vedotin-for-relapsed-or-refractory-hodgkinrsquos-lymphoma-peer-reviewed-article-DDDT |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|